Literature and evidence database
Find the source, the model and the boundary.
Search source records connected to the product-family knowledge base. Filter by category, product, publication year, research type, study model and editorial evidence tier.
Product evidence maps
A focused source set for each product.
Search and filter
Evidence records
Narrow the records by product, year or study model. Open each source to check its results and limitations.
REIMAGINE 2 cagrilintide-semaglutide comparative phase 3 study
2026 comparative trial; PMID 42251859.
ZEPBOUND (tirzepatide) prescribing information
U.S. FDA. Revised 2026. NDA 217806.
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
N Engl J Med. 2025. PMID 40544433.
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
N Engl J Med. 2025. PMID 40544432.
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, et al. N Engl J Med. 2022;387:205–216. PMID 35658024.
Once-weekly cagrilintide for weight management in people with overweight and obesity
Lau DCW, et al. The Lancet. 2021;398:2160–2172. PMID 34798060 · DOI 10.1016/S0140-6736(21)01751-7
Editorial methodology
How records are classified
Records are deduplicated by source URL and linked to every relevant product family. Study type and model are inferred from the citation and editorial evidence label, then reviewed during content QA.
Read the full editorial, AI-assistance and correction policy →
Labels and databases supporting regulatory status, formulation or chemical identity.
Controlled trials, systematic reviews and other clinical records with population-specific interpretation.
Animal, cell, analytical and mechanistic records that cannot establish human outcomes.
Narrative reviews, registries and sponsor reports kept visibly distinct from peer-reviewed outcomes.
Use the records